The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Phase 3 Completed 1200 enrolled Institute of Medical Biology, Chinese Academy of Medical Sciences Hebei Provincial Center for Diseases Control and Prevention · collab

RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) that do not contains Preservative .

Timeline

Start: 2012-03
Primary completion: 2012-05
Completion: 2012-08

Publications

Jing-Xia G, Yu-Liang Z, Jin-Feng L, Shu-Zhen L, Guo-Yang L, Qi L. Safety and effectiveness assessment of 2011-2012 seasonal influenza vaccine produced in China: a randomized trial. Postgrad Med. 2017 Nov;129(8):907-914. doi: 10.1080/00325481.2017.1369133. Epub 2017 Sep 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Influenza Virus Vaccine	Vaccine	0.5 ml	Intramuscular

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)

Summary

Timeline

Publications

Drugs

Indications